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Summary Eight children treated between 1977 and 1983 with the UK Children's Cancer Study Group's non-
Hodgkin lymphoma (NHL) and T-cell protocols have developed second malignancies within 7 years of
commencing treatment. Five developed acute non-lymphoblastic leukaemia and a sixth died from infection
while pancytopenic with a pre-leukaemic marrow. The other malignancies were cerebral astrocytoma and an
undifferentiated low grade sarcoma.
These eight children were included among 261 children studied in the first UKCCSG NHL and T-cell trials
giving an actuarial incidence of 7.8% second malignancy at 7 years. Six had received adjuvant radiotherapy
which may have contributed to the high incidence of second malignancy.
Children with non-Hodgkin's lymphoma (NHL) have been
shown to respond to intensive combination chemotherapy
based on schedules such as the LSA2-L2 protocol (Wollner
et al., 1976). The UK Children's Cancer Study Group
(UKCCSG) devised a similar protocol which was given to
children presenting between July 1977 and July 1983 with
NHL or T-cell leukaemia/lymphoma (Mott et al., 1984a, b).
Failure free survival rates at 4 years of 65% for children
without mediastinal disease and 37% for T-cell
leukaemia/lymphoma were achieved.
Recently three children treated with these protocols were
reported to have developed acute myeloid leukaemia
(Haworth et al., 1985; Rose et al., 1985; Darbyshire & Mott,
1986). We report 3 additional patients with acute leukaemia
or pre-leukaemia and 2 other cases of second malignancy viz:
cerebral astrocytoma and undifferentiated sarcoma. A
Kaplan-Meier estimate of the risk of second malignancy is
derived for these 8 patients.
Patients, protocols and methods
The protocols are shown in Figure 1. Remission was induced
with two courses of cyclophosphamide, adriamycin, vin-
cristine and prednisolone followed by cytosine and thio-
guanine. The remission was consolidated with intermediate
dose intravenous methotrexate, with additional asparaginase,
vincristine and prednisolone for the T-cell patients. Intra-
thecal methotrexate was given as prophylaxis for meningeal
disease, together with cranial radiotherapy for T-cell disease
and patients were allocated at random either to no further
treatment or to low dose radiation (15Gy) to the initial sites
of bulk disease. This was followed by maintenance chemo-
therapy including the alkylating agents cyclophosphamide
and CCNU. Total treatment time from first diagnosis was 2
years.
There were 261 patients registered in the UKCCSG
studies, 166 treated with NHL, 95 with the T-cell protocol.
The eight second malignancies reported here were among
these 261 patients. Their case records and histological
specimens have been reviewed. The staging system is that of
Murphy and Hustu (1980). The three patients reported
previously were case 4 (Haworth et al., 1985), case 5
(Darbyshire & Mott, 1986) and case 6 (Rose et al., 1985).
Table I summarises the initial presentation of the 8
patients. Histological review of the axillary lymph node
biopsy of case 2 led to the diagnosis being changed from
NHL to diffuse sclerosing Hodgkin's disease. Case 3 was
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originally diagnosed as NHL but as 56% of the marrow cells
were lymphoblasts, he actually had leukaemia. This was not
fully characterised; the blasts were large (13.5mu), of L2
morphology and they did not react with PAS, Sudan Black
or with acid phosphatase stains. Electron microscopy showed
features of B-cell leukaemia, but cell marker studies were not
available. He rapidly developed meningeal disease and received
additional intrathecal methotrexate, craniospinal radio-
therapy and further chemotherapy for bone marrow relapse.
The original diagnosis was confirmed in all the other cases
and the T-cell character of the initial material from cases 5
and 6 was confirmed by monoclonal antibody studies.
The seventh child in this report also suffered from Bloom's
syndrome with characteristic chromosome abnormalities
including excess sister chromatid exchanges.
A ninth patient not included in the tables was a boy aged
3 years who presented with proptosis and a retro-orbital
mass confirmed as NHL on biopsy. He was treated with the
NHL protocol together with adjuvant radiotherapy (30Gy)
to the orbit. He subsequently developed an acute undiffer-
entiated leukaemia, not fully characterised, after an interval
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Figure 1 UKCCSG protocol for NHL and T-cell leukaemia.
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Table I Second malignancy after treatment on UKCCSG NHL/T-cell protocol
Lymphoma Interval
Sex, age at and stage UKCCSG (years)
diagnosis of Presentation leukaemia & (%) chemo- forfirst
first tumour diagnostic white cell Marrow therapy to second Second
(years) tissue count blasts protocol Radiotherapy malignancy malignancy
1. Male Subcutaneous deposits in NHL (III) 0 NHL 15Gy to cranium, 3.0 AMoL
8.5 neck, back and scalp. neck and back.
Lumbar mass biopsied.
2. Female Anaemia, lymphadenopathy Hodgkin's A 'few' NHL 4.0 Myxoid
9.0 and mediastinal mass. disease in sarcoma
Axillary node biopsied. trephine Pouch of
Douglas.
3. Male Proptosis, hepatomegaly ALL 56 T-Cell 3.75Gy to orbits 6.1 Astrocytoma
1.9 and renal mass. (38.4x 1091-1) 15.84Gy to spine
Diagnosis by bone marrow. 20Gy to cranium
4. Male Intussusception. NHL (II) 0 NHL l5Gy to abdomen 4.9 AMML
11.1 Resection 6" of ileum
and caecum.
5. Male Lymphadenopathy and NHL (IV) 11.5 T-Cell 2Gy to mediastinum 3.0 AMML
8.4 mediastinal mass. 18Gy to cranium
Diagnosis by bone
marrow and lymph node
biopsy.
6. Male Mediastinal mass, pleural ALL 100 T-Cell 15Gy to 1.5 AMML
7.3 and pericardial (232 x 1091-1) mediastinum
effusions. Diagnosis 18Gy to cranium
by bone marrow.
7. Male Intussusception. Resection NHL (III) 0 NHL 15Gy to abdomen 3.0 Pre-leukaemia
12.4 of caecal mass. Bloom's
syndrome.
8. Male Cervical lymph nodes NHL (II) 0 NHL 3.2 AML
13.9
of 4.7 years and did not respond to chemotherapy. He was
not included in the analysis as he was not registered for the
trial.
Results
The child with Hodgkin's disease but treated with the
NHL protocol subsequently developed a myxoid sarcoma.
This was of different histological characteristics from the
malignant fibrous histiocytoma reported in another series
(Suster, 1986). Case 3, with early meningeal disease
developed a secondary cerebral astrocytoma and died
without further treatment.
Six of the eight patients developed acute myeloid
leukaemia or pre-leukaemia, the characteristics of which are
given in Table II. The last case developed acute myeloblastic
leukaemia but the other five cases all had monocytic or
myelomonocytic features. The child described in case 7 had
severe neutropenia for several months and marrows taken
during this time showed evolution towards M4 myeloid
leukaemia. The leukaemic cells in two patients had chromo-
some abnormalities, including an 11:16 translocation in one.
Further chemotherapy was given to 6 of the 8 children.
The girl who developed the undifferentiated sarcoma
responded to a combination of ifosfamide, etoposide and cis-
platinum. Two of the children with acute myelomonocytic
leukaemia remain in complete remission. Case 1 was treated
on the basis of the BFM protocol (Creutzig et al., 1985) for
acute myeloid leukaemia and case 5 has had a successful
bone marrow transplant after partial response to cytosine
arabinoside and etoposide. He was conditioned with cyclo-
phosphamide and irradiation before grafting from his HLA
identical brother.
These 8 patients who developed second malignancy
include 7 boys and 1 girl, whereas the trial had a ratio of 3:1
boys. If the girl is excluded as she did not have NHL or
T-cell leukaemia then it might be surmised that boys are
at special risk of developing secondary disease, especially
myeloid leukaemia. The mean age of the children in this
report (9 years) does not differ significantly from that in the
trial (8 years).
The incidence of second malignancy based on Kaplan-
Meier statistical analysis (Kaplan & Meier, 1958), is shown
in Figure 2 and shows a risk of 7.8% at seven years. A
similar analysis excluding case 8, the boy with Bloom's
syndrome (see Discussion) gives an incidence of 6.7% at
seven years.
Discussion
This paper describes a relatively high incidence of secondary
myeloid leukaemia in a group of children with NHL. A
previous study (Mike et al., 1982) included 1,050 children
treated for NHL and followed for up to 20 years and did
not describe any patients with secondary myeloid leukaemia.
A later review by the same late effects study group
(Meadows et al., 1985) describes one child with leukaemia
among 12 second malignancies in patients surviving NHL.
However, all the children in this paediatric series were
diagnosed before 1970, and had not therefore received the
kind of chemotherapy which has so greatly improved
prognosis subsequently (Wollner et al., 1976). There were no
cases of myeloid leukaemia in a series of 31 second
malignancies among 630 adults treated for NHL
(MacDougall et al., 1981).
A recent editorial (Lancet, 1985) however, has commented
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Table II Characteristics of the leukaemias/pre-leukaemia occurring after treatment of NHL or T-ALL
Case I Case 4 Case S Case 6 Case 7 Case 8
White cell count x 1091-1 2.7 2.8 7.4 112 1.0 2.2
Marrow blasts (%) 85 40 12 90 6 40
Morphology Large blasts Abnormal Mixed myeloid Large pleo- Abnormal Abnormal
with basophilic myeloid forms and nomocytoid morphic myelopoiesis myeloid forms
cytoplasm differentiation blast cells
Histochemistry
PAS -ve -ve -ve -ve -ve -ve
Sudan Black -ve -ve -ve -ve -ve +ve
Non-specific esterase +ve +ve in 30% Mixed +ve -ve +ve in 30%
T-cell markers
Tdt -ve 0% -ve -ve
Pan T, Tll -ve 39% -ve 1%
Common ALL -ve
Myeloid markers
My906, OKM-1 90% 73% 48% 60%
HLA-DR 94% 86%
Fab classification M5 M4 M4 M4 Pre-leukaemia M2
(M4)
Chromosomes 46XY 47XY+21+e-3 46XY t(ll.16)
17q-21q+
Treatment DR, VP16 CA VC, Pred ASP, 6MP CP, VP16 allogeneic VC, Pred None Mitoxantrone ar
CA, VP16 vindesine marrow transplant ADR CP CA
ASP, TG and
CA
Response Remission >1 year 2 brief remissions Remission >2 years Remission 4 Died Not yet evaluate
followed by death months,
in relapse relapsed and
died
ADR =adriamycin; ASP=asparaginase; CA=cytosine arabinoside; CP =cyclophosphamide; DR =daunorubicin; 6MP=mercaptopurii
Pred =prednisolone; TG=thioguanine; VC =vincristine; VPl6 =etoposide; AT =azathioprine.
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Figure 2 Time to second malignancy (Figures indicate patients
at risk at each event in the study).
patients. Evidence of myeloid leukaemia arising in adult
patients treated for both Hodgkin's disease and NHL is
described by Pedersen-Bjergaard et al. (1985) with the report
of 16 NHL patients developing myeloid leukaemia and by
Michels et al. (1985) who reported 4 such patients. These
papers also comment on the incidence of leukaemia after
Hodgkin's disease. The earlier review by Grunwald &
Rosner (1982) had already collated an extensive series of 216
cases of Hodgkin's disease who developed acute myeloid
leukaemia. This paper is especially relevant to our study as it
shows a high proportion of myeloblastic leukaemia (45%)
similar to the high incidence of M2 leukaemia shown by
Michels (1985) in contrast to our results. Also, the paper
attempts to show that the majority of their patients had
received both alkylating agents and radiotherapy as had our
patients.
The association of radiotherapy with second malignancy is
well known. One report (Potish et al., 1985) gave a relatively
low estimate of 9.6% 30 years after megavoltage irradiation
of children but included only one child with NHL.
Six of our eight children had received radiotherapy either
as cranial prophylaxis for T-cell disease, as emergency
treatment for proptosis or as adjuvant radiotherapy to local
disease.
Our estimate of 7.8% at 7 years from a population of 261
children treated with the UKCCSG regimens indicates a
significant risk of second malignancies in children surviving
NHL after these treatments. The graph has not yet reached a
stable plateau and a longer period of observation may show
further second malignancies. It is of interest and perhaps
predictable that one of the children described had Bloom's
syndrome, which is known to predispose to malignancy
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(Sawitsky et al., 1966), but even if this child is excluded our
estimate gives an incidence of 6.7% second malignancies at 7
years. A comparable figure of 9.9% at 9 years was reported
in adult Hodgkin's disease (Pedersen-Bjergaard & Larsen,
1982).
The secondary leukaemias described in our series had
chromosome abnormalities documented in two of the three
cases studied. Similar findings were reported in the studies of
Michels (1985) and Pedersen-Bjergaard et al. (1984).
Further trials of treatment for NHL in children should
examine the potential role of intensive chemotherapy and
radiotherapy as causative agents of secondary malignancy,
especially myelomonocytic leukaemia in boys. Adjuvant
radiation was discontinued by our Group on the basis of the
results of these randomised trials (Mott et al., 1984a, b). It
will be informative to follow the group who received no
adjuvant radiation, both in the trial cohort and in the
subsequent patients who received a modified chemotherapy
regimen.
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